CTOs on the Move

PharmaCord

www.pharmacord.com

 
PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharmacord.com
  • 6100 Dutchmans Lane 12th Floor
    Louisville, KY USA 40205
  • Phone: 502.805.3400

Executives

Name Title Contact Details
Jun Liu
Chief Technology Officer Profile

Similar Companies

california treats inc

california treats inc is a South El Monte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

westwood laboratories

westwood laboratories is a Azusa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karalex Pharma

Karalex Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.

Merz

Merz Pharmaceuticals is an innovative pharmaceutical company specializing in the research and marketing of drugs for the treatment of